Group One Trading
ADCT icon

Group One Trading’s ADC Therapeutics ADCT Stock Holding History

Group One Trading’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$107 Hold
100
– – ﹤0.01% 7403
2026
Q1 		$375 Hold
100
– – ﹤0.01% 7345
2025
Q4 		$353 Buy
+100
New +$406 ﹤0.01% 7845
2024
Q2 		– Sell
-4,787
Closed -$19K – 6621
2024
Q1 		$21.5K Buy
4,787
+2,555
+114% +$9.42K ﹤0.01% 5363
2023
Q4 		$3.71K Hold
2,232
– – ﹤0.01% 6626
2023
Q3 		$2K Buy
2,232
+2,137
+2,249% +$2.84K ﹤0.01% 7045
2023
Q2 		$204 Hold
95
– – ﹤0.01% 7468
2023
Q1 		$185 Sell
95
-805
-89% -$2.97K ﹤0.01% 6997
2022
Q4 		$3.46K Hold
900
– – ﹤0.01% 6488
2022
Q3 		$4K Buy
+900
New +$6.52K ﹤0.01% 6884
2022
Q1 		– Sell
-100
Closed -$1.59K – 7950
2021
Q4 		$2K Buy
+100
New +$2.41K ﹤0.01% 7852
2021
Q3 		– Sell
-200
Closed -$5.12K – 8096
2021
Q2 		$5K Hold
200
– – ﹤0.01% 7738
2021
Q1 		$5K Sell
200
-200
-50% -$5.79K ﹤0.01% 7224
2020
Q4 		$13K Buy
+400
New +$13.1K ﹤0.01% 5685

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Group One Trading's ADCT Position: Q2 2026 in Review

Group One Trading held its ADC Therapeutics (ADCT) position steady in Q2 2026 at 100 shares worth $107. The position accounts for ﹤0.01% of the portfolio, ranked #7403.

Group One Trading first reported a position in ADCT in Q4 2020 and has held it in 14 quarters since. The position peaked at $21.5K in Q1 2024. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Group One Trading held 100 shares of ADC Therapeutics worth $107 as of Q2 2026.
  • Group One Trading left its ADC Therapeutics share count unchanged in Q2 2026.
  • ADC Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #7403 holding.
  • Group One Trading first reported a position in ADC Therapeutics in Q4 2020 and has held it in 14 quarters since.
  • Group One Trading's ADC Therapeutics position peaked at $21.5K in Q1 2024.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.